Dr. Ying Liu 柳影
Chief Physician
Department of Medical Oncology, Jilin Cancer Hospital, Changchun
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical focus on lung cancer, breast cancer, and malignant lymphoma. Engages in basic and clinical research for solid tumors.
Dr. Liu holds a PhD and graduated from Bethune Medical University in 1993. Since joining Jilin Cancer Hospital, Dr. Liu has served as Director of the Second Ward, Department of Thoracic Medical Oncology. Research includes studies on thalidomide for non-Hodgkin lymphoma and gene detection for breast cancer. Dr. Liu has participated in over 80 multi-center clinical trials.
Professional roles
- Member and Secretary, Small Cell Lung Cancer Expert Committee, Clinical Collaboration Center (CSCO), China Anti-Cancer Association
- Youth Member, Lung Cancer Professional Committee, China Anti-Cancer Association
- Secretary, Oncology Professional Committee, Jilin Medical Association
- Secretary, Chemotherapy Professional Committee, Jilin Anti-Cancer Association
Name order: in Chinese the family name comes first (Liu Ying). Papers usually list the name as Ying Liu or Liu Y.
Selected publications
45 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Ann Med, 2026 (first author): Clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboring SMARCA4 mutations. PubMed 41593906
- Cancer Commun (Lond), 2026 (first author): Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial. PubMed 43011476
- Curr Opin Oncol, 2026 (senior author): Recent advances in treating small-cell lung cancer. PubMed 43021706
- Clin Lung Cancer, 2026 (first author): Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial. PubMed 42480250
- J Thorac Dis, 2026 (first author): Real-world evidence on the efficacy, safety, and biomarkers of immunotherapy combined with radiotherapy in limited-stage small cell lung cancer. PubMed 41816449
- Int J Colorectal Dis, 2025 (first author): The efficacy and safety of suvemcitug, envafolimab, and FOLFIRI in microsatellite-stable or mismatch repair-proficient colorectal cancer: preliminary results of a phase 2 study. PubMed 39836256
- Cancer Treat Res Commun, 2024 (first author): Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies. PubMed 39823755
- Future Oncol, 2024 (first author): Navigating first-line therapies for extensive-stage small-cell lung cancer: a frequentist network meta-analysis and systematic review. PubMed 39072397
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion